Relationship between Duffy Antigen Receptor for Chemokines and Clinical Characteristics in Han People with Chronic Hepatitis C Infection in Dalian, China
Open Access
- 14 October 2020
- journal article
- research article
- Published by DoNotEdit in Iranian Red Crescent Medical Journal
- Vol. 22 (10)
- https://doi.org/10.32592/ircmj.2020.22.10.146
Abstract
Background and Objectives: Most patients with untreated chronic hepatitis C virus (HCV) infection develop hepatic fibrosis. Hepatic disease progression is monitored with hematological markers (alanine aminotransferase [ALT], aspartate aminotransferase [AST], albumin and platelet [PLT] count, AST/ALT ratio, AST/PLT ratio index [APRI], and fibrosis 4 score [FIB-4]) and FibroScan. The present study aimed to investigate the association between Duffy antigen/chemokines receptor (DARC) polymorphisms and clinical parameters in the Han people with chronic hepatitis C infection in Dalian, China. Materials and Methods: This cohort study was performed on 245 Han people with chronic HCV at Dalian infectious hospital during April-December 2015. The participants of the research were selected using the consecutive sampling method. The DARC genotyping was performed using the TaqMan probe method and transient elastography was measured by FibroScan. Results: Based on the findings, DARC polymorphisms correlated with ALT concentrations (FY*A/FY*A vs. FY*A/FY*B, P=0.025). However, the DARC polymorphism did not have an association with HCV RNA titers (FY*A/FY*A vs. FY*A/FY*B, P=0.241) or hepatic fibrosis (FY*A/FY*A vs. FY*A/FY*B, P=0.325). Moreover, correlation analyses showed that APRI (P<0.001, rho=0.603) and FIB-4 (P<0.001, rho=0.698) were useful predictors of hepatic fibrosis in chronic HCV infection. Besides, HCV RNA titers (P=0.327) and hepatic injury markers (P=0.814, 0.198, 0.767, and 0.171 for ALT, AST, ALB, and AST/ALT, respectively) were not useful for the estimation of the fibrosis stage in patients with chronic hepatitis C. Conclusion: The FY*A allele is a potentially valuable protective factor against hepatocyte damage in chronic HCV-infected patients.Keywords
This publication has 32 references indexed in Scilit:
- Does Incorporating Change in APRI or FIB-4 Indices Over Time Improve the Accuracy of a Single Index for Identifying Liver Fibrosis in Persons With Chronic Hepatitis C Virus Infection?Journal of Clinical Gastroenterology, 2018
- Atypical Chemokine Receptor 1 Polymorphism can not Affect Susceptibility to Hepatitis C VirusBalkan Medical Journal, 2017
- Association of MBOAT7 gene variant with plasma ALT levels in children: the PANIC studyPediatric Research, 2016
- FibroScan, APRI, FIB4, and GUCI: Role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infectionArab Journal of Gastroenterology, 2016
- AST/ALT ratio is not useful in predicting the degree of fibrosis in chronic viral hepatitis patientsEuropean Journal of Gastroenterology & Hepatology, 2015
- Distinct Transcript Isoforms of the Atypical Chemokine Receptor 1 (ACKR1) / Duffy Antigen Receptor for Chemokines (DARC) Gene Are Expressed in Lymphoblasts and Altered Isoform Levels Are Associated with Genetic Ancestry and the Duffy-Null AllelePLOS ONE, 2015
- Meta-analysis reveals a specific association of the PNPLA3 I148M polymorphism with ALT level in adolescentsPersonalized Medicine, 2015
- AST/ALT ratio is not an index of liver fibrosis in chronic hepatitis C when aminotransferase activities are determinate according to the international recommendationsClinics and Research in Hepatology and Gastroenterology, 2013
- A Duffy antigen receptor for chemokines (DARC) polymorphism that determines pro-fibrotic chemokine serum concentrations is not directly associated with severity of hepatitis C infectionHuman Immunology, 2011
- Serum HCV-RNA levels in patients with chronic hepatitis C: Correlation with histological featuresArab Journal of Gastroenterology, 2009